- Home
- GNTA vs DYAI Comparison
GNTA vs DYAI Comparison
Compare GNTA & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNTA | DYAI |
|---|---|---|
| Founded | 2014 | 1979 |
| Country | Italy | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.0M | 30.8M |
| IPO Year | N/A | 2003 |
Fundamental Metrics
Financial Performance| Metric | GNTA | DYAI |
|---|---|---|
| Price | $1.00 | $0.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | ★ 625.8K | 37.7K |
| Earning Date | 01-01-0001 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,495,389.00 |
| Revenue This Year | N/A | $12.52 |
| Revenue Next Year | N/A | $92.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 20.58 |
| 52 Week Low | $0.71 | $0.71 |
| 52 Week High | $10.00 | $1.55 |
Technical Indicators
Market Signals| Indicator | GNTA | DYAI |
|---|---|---|
| Relative Strength Index (RSI) | 45.25 | 36.53 |
| Support Level | $0.71 | $0.71 |
| Resistance Level | $1.70 | $0.98 |
| Average True Range (ATR) | 0.11 | 0.04 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 85.53 | 31.62 |
Price Performance
Historical ComparisonAbout GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.